Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Familial platelet disorder with predisposition to acute myelogenous leukaemia (FPD/AML, MIM 601399) is an autosomal dominant disorder characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukaemia (AML). Informative recombination events in 6 FPD/AML pedigrees with evidence of linkage to markers on chromosome 21q identified an 880-kb interval containing the disease gene. Mutational analysis of regional candidate genes showed nonsense mutations or intragenic deletion of one allele of the haematopoietic transcription factor CBFA2 (formerly AML1) that co-segregated with the disease in four FPD/AML pedigrees. We identified heterozygous CBFA2 missense mutations that co-segregated with the disease in the remaining two FPD/AML pedigrees at phylogenetically conserved amino acids R166 and R201, respectively. Analysis of bone marrow or peripheral blood cells from affected FPD/AML individuals showed a decrement in megakaryocyte colony formation, demonstrating that CBFA2 dosage affects megakaryopoiesis. Our findings support a model for FPD/AML in which haploinsufficiency of CBFA2 causes an autosomal dominant congenital platelet defect and predisposes to the acquisition of additional mutations that cause leukaemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The transcription factor RUNX-1 plays a key role in megakaryocyte differentiation and is mutated in cases of myelodysplastic syndrome and leukemia.”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [48]
In the citing paper
“Germ line mutations in RUNX-1 cause familial platelet disorder with the propensity to develop acute myelogenous leukemia (FPD/AML), a rare autosomal dominant disorder characterized by quantitative and qualitative platelet defects and a high incidence of developing myelodysplastic syndrome (MDS) and leukemia”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [48]
Citations
Cites
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
de Thé, H., Chomienne, C., Lanotte, M., Degos, L., & Dejean, A. (1990) · Nature · doi:10.1038/347558a0 · Cited by 1,355 · cited 1×
“Fusion of PDGF Receptor β to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.”
BackgroundWang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H., & Speck, N. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3444 · Cited by 1,178
Self-citationGolub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Self-citationOncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis.
Weinberg, R. A. (1989) · PubMed · Cited by 949
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 784
Fusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia
Liu, P., Tarlé, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., & Collins, F. S. (1993) · Science · doi:10.1126/science.8351518 · Cited by 732 · cited 1×
“; the CBFB / MYH11 fusion associated with inv(16) myelomonocytic leukaemia with eosinophili”
BackgroundFusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.
Golub, T. R., Barker, G. F., Bohlander, S. K., Hiebert, S. W., Ward, D. C., Bray-Ward, P., Morgan, E., Raimondi, S. C., Rowley, J. D., & Gilliland, D. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4917 · Cited by 704
Self-citationShivdasani, R. A., Rosenblatt, M. F., Zucker-Franklin, D., Jackson, C. W., Hunt, P., Saris, C. J. M., & Orkin, S. H. (1995) · Cell · doi:10.1016/0092-8674(95)90531-6 · Cited by 693 · cited 1×
“It is notable that mice hemizygous for genes required for megakaryopoiesis, such as Gata1 , Nfe2 and fog , have apparent platelet defect”
BackgroundShivdasani, R. A., Fujiwara, Y., McDevitt, M. A., & Orkin, S. H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3965 · Cited by 674 · cited 1×
“It is notable that mice hemizygous for genes required for megakaryopoiesis, such as Gata1 , Nfe2 and fog , have apparent platelet defect”
Background
Cited by
A molecular signature of metastasis in primary solid tumors
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003) · Nature Genetics · doi:10.1038/ng1060 · Cited by 2,449
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Greenberg, P. L., Attar, E. C., Bennett, J. M., Bloomfield, C. D., Borate, U., Castro, C. M. D., Deeg, H. J., Frankfurt, O., Gaensler, K. M. L., Garcia-Manero, G., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0104 · Cited by 1,639
Causal Relationship between the Loss of RUNX3 Expression and Gastric Cancer
Li, Q.-L., Ito, K., Sakakura, C., Fukamachi, H., Inoue, K.-I., Chi, X.-Z., Lee, K.-Y., Nomura, S., Lee, C.-W., Han, S.-B., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00690-6 · Cited by 1,028
“To overcome this problem, we obtained cell lines from epithelial cells have been described (Osato et al., 1999; Song et al., 1999).”
MethodAcquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome
Wechsler, J., Greene, M., McDevitt, M. A., Anastasi, J., Karp, J. E., Le Beau, M. M., & Crispino, J. D. (2002) · Nature Genetics · doi:10.1038/ng955 · Cited by 760
“2) [5]/47,XY,+21c[14] 173–174 ins 15 bp Tyr62”
Hsu, A. P., Sampaio, E. P., Khan, J., Calvo, K. R., Lemieux, J. E., Patel, S. Y., Frucht, D. M., Vinh, D. C., Auth, R. D., Freeman, A. F., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356352 · Cited by 638
Disruption of differentiation in human cancer: AML shows the way
Tenen, D. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc989 · Cited by 612
Ichikawa, M., Asai, T., Saito, T., Yamamoto, G., Seo, S., Yamazaki, I., Yamagata, T., Mitani, K., Chiba, S., Hirai, H., et al. (2004) · Nature Medicine · doi:10.1038/nm997 · Cited by 596
North, T. E., de Bruijn, M. F. T. R., Stacy, T., Talebian, L., Lind, E., Robin, C., Binder, M., Dzierzak, E., & Speck, N. A. (2002) · Immunity · doi:10.1016/s1074-7613(02)00296-0 · Cited by 583
“5 Runx1lz/ embryos and in the AGM region were located primarily into Runx1 dosage (Cai et al., 2000; Hayashi et al., 2000; Mukouyama et al., 2000; Song et al., 1999; Wang et al., the paraaortic mesenchyme (Figure 2A).”
BackgroundSelf-citationCore-binding factors in haematopoiesis and leukaemia
Speck, N. A., & Gilliland, D. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc840 · Cited by 569
Self-citationKLF4, p21 and context-dependent opposing forces in cancer
Rowland, B. D., & Peeper, D. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1780 · Cited by 551
Whole-genome sequencing of patients with rare diseases in a national health system
Turro, E., Astle, W. J., Megy, K., Gräf, S., Greene, D., Shamardina, O., Allen, H. L., Sanchis-Juan, A., Frontini, M., Thys, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2434-2 · Cited by 554
G ENETICS OF M YELOID L EUKEMIAS
Kelly, L. M., & Gilliland, D. G. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.032802.115046 · Cited by 523
Self-citationLerman, M. I., & Minna, J. D. (2000) · PubMed · Cited by 632
Ostergaard, P., Simpson, M. A., Connell, F. C., Steward, C. G., Brice, G., Woollard, W. J., Dafou, D., Kilo, T., Smithson, S., Lunt, P., et al. (2011) · Nature Genetics · doi:10.1038/ng.923 · Cited by 506
Divergence and convergence of TGF‐β/BMP signaling
Miyazono, K., Kusanagi, K., & Inoue, H. (2001) · Journal of Cellular Physiology · doi:10.1002/jcp.1080 · Cited by 505
“Germ-line mutations of the Runx1/AML1 gene are responsible for the human familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML) (Song et al., 1999).”
BackgroundRole of RUNX1 in hematological malignancies
Sood, R., Kamikubo, Y., & Liu, P. (2017) · Blood · doi:10.1182/blood-2016-10-687830 · Cited by 494
“11 However, the partner genes have been identified in less than half of these translocations.11 RUNX1 somatic mutations in MDS It took8years since thefirst report ofRUNX1 involvement in leukemias by chromosomal rearrangements to identify somatic and germ line RUNX1 mutations in MDS, AML without translocations, and FPD…”
BackgroundResultInfluentialThe genetics and mechanisms of T cell acute lymphoblastic leukaemia
Belver, L., & Ferrando, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.63 · Cited by 446
AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia
Pabst, T., Mueller, B. U., Harakawa, N., Schoch, C., Haferlach, T., Behre, G., Hiddemann, W., Zhang, D.-E., & Tenen, D. G. (2001) · Nature Medicine · doi:10.1038/86515 · Cited by 463
Gaidzik, V. I., Bullinger, L., Schlenk, R. F., Zimmermann, A. S., Röck, J., Paschka, P., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7926 · Cited by 456
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype
Growney, J. D., Shigematsu, H., Li, Z., Lee, B. H., Adelsperger, J., Rowan, R., Curley, D. P., Kutok, J. L., Akashi, K., Williams, I. R., et al. (2005) · Blood · doi:10.1182/blood-2004-08-3280 · Cited by 462
Self-citationThe runx genes: gain or loss of function in cancer
Blyth, K., Cameron, E. R., & Neil, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1607 · Cited by 455
Gene expression profiling of pediatric acute myelogenous leukemia
Ross, M. E., Mahfouz, R., Onciu, M., Liu, H.-C., Zhou, X., Song, G., Shurtleff, S. A., Pounds, S., Cheng, C., Ma, J., et al. (2004) · Blood · doi:10.1182/blood-2004-03-1154 · Cited by 448
Higuchi, M., O'Brien, D., Kumaravelu, P., Lenny, N., Yeoh, E.-J., & Downing, J. R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00016-8 · Cited by 440
Wlodarski, M. W., Hirabayashi, S., Pastor, V., Starý, J., Hasle, H., Masetti, R., Dworzak, M., Schmugge, M., van den Heuvel-Eibrink, M., Ussowicz, M., et al. (2016) · Blood · doi:10.1182/blood-2015-09-669937 · Cited by 392
MicroRNA fingerprints during human megakaryocytopoiesis
Garzon, R., Pichiorri, F., Palumbo, T., Iuliano, R., Cimmino, A., Aqeilan, R., Volinia, S., Bhatt, D., Alder, H., Marcucci, G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600587103 · Cited by 414
The RUNX family: developmental regulators in cancer
Ito, Y., Bae, S.-C., & Chuang, L. S. H. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3877 · Cited by 399
Linking the epigenetic ‘language’ of covalent histone modifications to cancer
Hake, S. B., Xiao, A., & Allis, C. D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601575 · Cited by 385
“Histone acetylation and methylation ‘Switch’ marks”
BackgroundGermline ETV6 mutations in familial thrombocytopenia and hematologic malignancy
Zhang, M. Y., Churpek, J. E., Keel, S. B., Walsh, T., Lee, M. K., Loeb, K. R., Gulsuner, S., Pritchard, C. C., Sanchez-Bonilla, M., Delrow, J. J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3177 · Cited by 367
Michaud, J. (2002) · Blood · doi:10.1182/blood.v99.4.1364 · Cited by 367
“For functional studies of mutated RUNX1 proteins, the wild-type RUNX1 sequence (1-453) was inserted into the pEF-BOS mammalian expression plasmid.”
MethodMolecular Genetics of Acute Lymphoblastic Leukemia
Armstrong, S. A., & Look, A. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.047 · Cited by 362
Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease
Leeuwen, I. S. L.-V., Dauwerse, J. G., Baelde, H. J., Leonhard, W. N., van de Wal, A., Ward, C. J., Verbeek, S., DeRuiter, M. C., Breuning, M. H., de Heer, E., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh336 · Cited by 352
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
Fröhling, S., Scholl, C., Gilliland, D. G., & Levine, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.010 · Cited by 353
Self-citationCooperating gene mutations in acute myeloid leukemia: a review of the literature
Renneville, A., Roumier, C., Biggio, V, Nibourel, O., Boissel, N., Fenaux, P., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.19 · Cited by 351
Peroxisome proliferator-activated receptor gamma and cancers.
Koeffler, H. P. (2003) · PubMed · Cited by 402
Myelodysplastic Syndromes — Coping with Ineffective Hematopoiesis
Cazzola, M., & Malcovati, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmp048266 · Cited by 343
Pollyea, D. A., Bixby, D., Perl, A., Bhatt, V. R., Altman, J. K., Appelbaum, F. R., de Lima, M., Fathi, A. T., Foran, J. M., Gojo, I., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0002 · Cited by 320
Noetzli, L., Lo, R. W., Lee-Sherick, A. B., Callaghan, M., Noris, P., Savoia, A., Rajpurkar, M., Jones, K., Gowan, K., Balduini, C. L., et al. (2015) · Nature Genetics · doi:10.1038/ng.3253 · Cited by 331
“3 Some familial platelet disorders are associated with predisposition to leukemia, myelodysplastic syndrome (MDS) or dyserythropoietic anemia.(1,2) We have identified a family with autosomal dominant thrombocytopenia, high red blood cell mean corpuscular volume (MCV) and two”
BackgroundMutation of CEBPA in Familial Acute Myeloid Leukemia
Smith, M. L., Cavenagh, J. D., Lister, T. A., & Fitzgibbon, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041331 · Cited by 328
Nimer, S. D. (2008) · Blood · doi:10.1182/blood-2007-08-078139 · Cited by 336
RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation.
Elagib, K. E., Racke, F. K., Mogass, M., Khetawat, R., Delehanty, L. L., & Goldfarb, A. N. (2003) · Blood · doi:10.1182/blood-2002-09-2708 · Cited by 332
Tahirov, T. H., Inoue-Bungo, T., Morii, H., Fujikawa, A., Sasaki, M., Kimura, K., Shiina, M., Sato, K., Kumasaka, T., Yamamoto, M., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00271-9 · Cited by 327
“…were also confirmed using complexes coninto acute myelogenous leukemia (FPD/AML) has also taining three heavy atom derivatives of the DNA fragments in which been reported (Song et al., 1999). four, five, or six deoxythymidines were replaced with 5-iodo deoxy- uracils at the corresponding positions.”
BackgroundAcute myeloid leukemia stem cells and CD33-targeted immunotherapy
Walter, R. B., Appelbaum, F. R., Estey, E. H., & Bernstein, I. D. (2012) · Blood · doi:10.1182/blood-2011-11-325050 · Cited by 321
“GOELAMS AML 2006 IR114 AML (intermediate risk) 238 18-60 (50) GO (6 mg/m2) on day 1 with”
BackgroundRUNX transcription factors as key targets of TGF-β superfamily signaling
Ito, Y., & Miyazono, K. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(03)00007-8 · Cited by 324
Oncogenic potential of the RUNX gene family: ‘Overview’
Ito, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1207755 · Cited by 316
GATA-2 Plays Two Functionally Distinct Roles during the Ontogeny of Hematopoietic Stem Cells
Ling, K.-W., Ottersbach, K., van Hamburg, J. P., Oziemlak, A., Tsai, F.-Y., Orkin, S. H., Ploemacher, R., Hendriks, R. W., & Dzierzak, E. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031556 · Cited by 316
“Moreover, haploinsufficiency of human Runx1 (AML-1) results in thromobocytopenia and a propensity to develop myeloid leukemia (21).”
BackgroundTijssen, M. R., Cvejic, A., Joshi, A., Hannah, R. L., Ferreira, R., Forrai, A., Bellissimo, D. C., Oram, S. H., Smethurst, P. A., Wilson, N. K., et al. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.04.008 · Cited by 289
“…other TFs investigated in this study, GATA2, RUNX1, FLI1, and SCL, have also been previously shown to play important roles in MK differentiation (Growney et al., 2005; Hart et al., 2000; Huang et al., 2009b; Ichikawa et al., 2004; Mik-kola et al., 2003; Song et al., 1999; Spyropoulos et al., 2000).”
Rainis, L. (2003) · Blood · doi:10.1182/blood-2002-11-3599 · Cited by 291
Kalev-Zylinska, M. L., Horsfield, J. A., Flores, M. V. C., Postlethwait, J. H., Vitas, M. R., Baas, A. M., Crosier, P. S., & Crosier, K. E. (2002) · Development · doi:10.1242/dev.129.8.2015 · Cited by 289
The Molecular Basis of Leukemia
Gilliland, D. G., Jordan, C. T., & Felix, C. A. (2004) · Hematology · doi:10.1182/asheducation-2004.1.80 · Cited by 273
Self-citationPattern of malignant disorders in individuals with Down's syndrome
Hasle, H. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00435-6 · Cited by 286
Ripperger, T., Bielack, S. S., Borkhardt, A., Brecht, I. B., Burkhardt, B., Calaminus, G., Debatin, K., Deubzer, H., Dirksen, U., Eckert, C., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38142 · Cited by 283
“, 2015), RUNX1 (Song et al., 1999), and ANKRD26 (MIM 610855, ankyrin repeat containing protein) deficiency (Noris et al.”
InfluentialHarada, H., Harada, Y., Niimi, H., Kyo, T., Kimura, A., & Inaba, T. (2004) · Blood · doi:10.1182/blood-2003-09-3074 · Cited by 281
Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl437 · Cited by 281
“The RUNX1 gene, also called AML1, encodes runt-related transcription factor 1, which is required for active repression in CD4-negative/ CD8-negative thymocytes, and a defective RUNX1 gene causes a familial platelet disorder with predisposition to acute myelogenous leukemia (31).”
BackgroundMendler, J. H., Maharry, K., Radmacher, M. D., Mrózek, K., Becker, H., Metzeler, K. H., Schwind, S., Whitman, S. P., Khalife, J., Kohlschmidt, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.6652 · Cited by 268
“This is possibly because of agerelated differences or because of the diverse cytogenetics of the patients in their study, including several patients with t(8;21)(q22;q22), inv(16)(p13q22), or t(15;17)(q24;q21), among others.”
BackgroundPoint mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia
Osato, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207779 · Cited by 268
“(Table 2) (Song et al., 1999; Michaud et al., 2002).”
BackgroundNew Insights Into the Differentiation of Megakaryocytes From Hematopoietic Progenitors
Noetzli, L. J., French, S. L., & Machlus, K. R. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312129 · Cited by 263
Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Kelly, L., Shigematsu, H., Johnson, L., Akashi, K., Tuveson, D. A., Jacks, T., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20476 · Cited by 270
“KM – 8–83 (35) 34–53 (41) 156–885 (583) 70–1,271 (540) 704–2,777 (1491) MPD n = 6 n = 6 n = 6 n = 8 n = 8”
BackgroundSelf-citationPreudhomme, C., Warot-Loze, D., Roumier, C., Grardel-Duflos, N., Garand, R., Lai, J. L., Dastugue, N., Macintyre, E., Denis, C., Bauters, F., et al. (2000) · Blood · doi:10.1182/blood.v96.8.2862 · Cited by 263
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.
Huang, G., Zhang, P., Hirai, H., Elf, S., Yan, X., Chen, Z., Koschmieder, S., Okuno, Y., Dayaram, T., Growney, J. D., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.7 · Cited by 259
“with this finding, the leukemogenic oncoprotein AML1/ETO, the fusion protein resulting from the t(8;21) chromosome translocation, inhibits PU.”
BackgroundSelf-citationLinggi, B., Müller-Tidow, C., van de Locht, L., Hu, M., Nip, J., Serve, H., Berdel, W. E., van der Reijden, B., Quelle, D. E., Rowley, J. D., et al. (2002) · Nature Medicine · doi:10.1038/nm726 · Cited by 258
Cai, Z., de Bruijn, M., Ma, X., Dortland, B., Luteijn, T., Downing, J. R., & Dzierzak, E. (2000) · Immunity · doi:10.1016/s1074-7613(00)00042-x · Cited by 254
Molecular genetics of B-precursor acute lymphoblastic leukemia
Mullighan, C. G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61203 · Cited by 247
“MYC rearrangement [t(8;14)(q24;q32), 2 Favorable prognosis with short-term, high-dose chemotherapy 70 t(2;8)(q12;q24)]”
Vangala, R. K., Heiss-Neumann, M. S., Rangatia, J. S., Singh, S. M., Schoch, C., Tenen, D. G., Hiddemann, W., & Behre, G. (2003) · Blood · doi:10.1182/blood-2002-04-1288 · Cited by 245
Heterozygous PU.1 mutations are associated with acute myeloid leukemia
Mueller, B. U., Pabst, T., Osato, M., Asou, N., Johansen, L. M., Minden, M. D., Behre, G., Hiddemann, W., Ito, Y., & Tenen, D. G. (2002) · Blood · doi:10.1182/blood.v100.3.998 · Cited by 243
Owen, C. J., Toze, C. L., Koochin, A., Forrest, D. L., Smith, C. A., Stevens, J. M., Jackson, S. C., Poon, M.-C., Sinclair, G. D., Leber, B., et al. (2008) · Blood · doi:10.1182/blood-2008-05-156745 · Cited by 242
“The nature of RUNX1 mutations in de novo MDS/AML appears similar to that seen in FPD/AML with a predominance of point mutations in the RHD.1,2,10,14 Regardless of the cause of MDS/AML, effective treatment options are limited, and the only curative therapy for MDS is hematopoietic stem cell transplantation (HSCT) with…”
BackgroundMethodInfluentialCai, X., Gao, L., Teng, L., Ge, J., Oo, Z. M., Kumar, A. R., Gilliland, D. G., Mason, P. J., Tan, K., & Speck, N. A. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.06.002 · Cited by 235
“…be early events is demonstrated unequivocally by the observation that Cell Stem Cell 17, 1–13, August 6, 2015 ª2015 Elsevier Inc. 1 FPD/AML patients who harbor germline mutations in RUNX1 have an 35% lifetime risk of developing MDS/AML (Ganly et al., 2004; Michaud et al., 2002; Song et al., 1999).”
Self-citationTomasson, M. H., Xiang, Z., Walgren, R., Zhao, Y., Kasai, Y., Miner, T., Ries, R. E., Lubman, O., Fremont, D. H., McLellan, M. D., et al. (2008) · Blood · doi:10.1182/blood-2007-09-113027 · Cited by 227
Yu, M., Mazor, T., Huang, H., Huang, H.-T., Kathrein, K. L., Woo, A. J., Chouinard, C. R., Labadorf, A., Akie, T. E., Moran, T. B., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2011.11.032 · Cited by 215
“Germline Runx1 haploinsufficiency causes familial thrombocytopenia, platelet dysfunction, and increased MDS/leukemia risk (Song et al., 1999).”
Javed, A., Guo, B., Hiebert, S., Choi, J.-Y., Green, J., Zhao, S.-C., Osborne, M. A., Stifani, S., Stein, J. L., Lian, J. B., et al. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.12.2221 · Cited by 233
Core-binding factors in hematopoiesis and immune function
de Bruijn, M. F., & Speck, N. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207763 · Cited by 231
“…as haploinsufficiency of RUNX1 causes a familial platelet disorder in humans characterized by reduced platelet numbers, prolonged bleeding times and abnormal responses to agonists of platelet aggregation (FPD/AML) (Luddy et al., 1978; Dowton et al., 1985; Gerrard et al., 1991; Song et al., 1999).”
BackgroundSelf-citationTumor suppressor genes in normal and malignant hematopoiesis
Krug, U., Ganser, A., & Koeffler, H. P. (2002) · Oncogene · doi:10.1038/sj.onc.1205322 · Cited by 231
“…5% of sporadic myeloid leukemia samples, with a high incidence occurring in those which are M0 subtype or myeloid malignancies with an acquired trisomy 21 (Osato et al., 1999; Preudhomme et al., 2000), and in a small subset of MDS and pediatric ALL samples (Song et al., 1999; Imai et al., 2000).”
BackgroundPasquet, M., Bellanné-Chantelot, C., Tavitian, S., Prade, N., Beaupain, B., LaRochelle, O., Petit, A., Rohrlich, P., Ferrand, C., Van Den Neste, E., et al. (2013) · Blood · doi:10.1182/blood-2012-08-447367 · Cited by 217
The Management of Neoplastic Disorders of Haematopoeisis in Children with Down's Syndrome
Lange, B. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02027.x · Cited by 230
“Also CBFA2/ AML-1 is implicated in the familial platelet disorder (FPD)/ AML syndrome (Legare et al, 1997; Song et al, 1999): in five families with this disorder, subtle deletions in CBFA2/AML-1 led to the haploinsufficiency of this gene and loss of function (Song et al, 1999).”
BackgroundPediatric AML: From Biology to Clinical Management
De Rooij, J., Zwaan, C., & Van den Heuvel-Eibrink, M. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4010127 · Cited by 208
“Recently, germ-line mutations in several genes, such as TP53, RUNX1, GATA2 and CEBPA, have been found in families with an unexplained high risk of AML, suggesting a familial predisposition to develop AML [4–8].”
BackgroundInherited thrombocytopenia: when a low platelet count does not mean ITP
Drachman, J. G. (2004) · Blood · doi:10.1182/blood-2003-05-1742 · Cited by 216
Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia
Churpek, J. E., Pyrtel, K., Kanchi, K.-L., Shao, J., Koboldt, D., Miller, C. A., Shen, D., Fulton, R., O’Laughlin, M., Fronick, C., et al. (2015) · Blood · doi:10.1182/blood-2015-04-641100 · Cited by 216
The genomic landscape of pediatric myelodysplastic syndromes
Schwartz, J. R., Ma, J., Lamprecht, T., Walsh, M., Wang, S., Bryant, V., Song, G., Wu, G., Easton, J., Kesserwan, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01590-5 · Cited by 210
Origins of leukaemia in children with Down syndrome
Hitzler, J. K., & Zipursky, A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1525 · Cited by 211
Tesi, B., Davidsson, J., Voss, M., Rahikkala, E., Holmes, T. D., Chiang, S. C. C., Komulainen-Ebrahim, J., Gorcenco, S., Rundberg Nilsson, A., Ripperger, T., et al. (2017) · Blood · doi:10.1182/blood-2016-10-743302 · Cited by 207
Jin, Y.-H., Jeon, E.-J., Li, Q.-L., Lee, Y. H., Choi, J.-K., Kim, W.-J., Lee, K.-Y., & Bae, S.-C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313120200 · Cited by 211
Pabst, T., Eyholzer, M., Haefliger, S., Schardt, J., & Mueller, B. U. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5563 · Cited by 201
Molecular genetics of human leukemias: New insights into therapy
Gilliland, D. G. (2002) · Seminars in Hematology · doi:10.1053/shem.2002.36921 · Cited by 203
Self-citationRunx transcription factors in the development and function of the definitive hematopoietic system
de Bruijn, M., & Dzierzak, E. (2017) · Blood · doi:10.1182/blood-2016-12-689109 · Cited by 209
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99002-8 · Cited by 203
Morrissey, C., Martinez, A., Zatyka, M., Agathanggelou, A., Honorio, S., Astuti, D., Morgan, N. V., Moch, H., Richards, F. M., Kishida, T., et al. (2001) · PubMed · Cited by 197
Chromosomal Deletions and Tumor Suppressor Genes in Prostate Cancer
Dong, J.-T. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1015575125780 · Cited by 192
“Haploinsufficiency is one mechanism underlying human genetic diseases [9,10].”
BackgroundFamilial myelodysplasia and acute myeloid leukaemia – a review
Owen, C., Barnett, M., & Fitzgibbon, J. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06909.x · Cited by 187
“First reported by Dowton et al (1985) in a large French-Canadian family, there have now been more than a dozen confirmed cases reported in the literature (Song et al, 1999; Michaud et al, 2002; Heller et al, 2005; Kirito et al, 2006).”
BackgroundInfluentialBourquin, J.-P., Subramanian, A., Langebrake, C., Reinhardt, D., Bernard, O., Ballerini, P., Baruchel, A., Cavé, H., Dastugue, N., Hasle, H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511150103 · Cited by 189
Payne, S. R., & Kemp, C. J. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi223 · Cited by 186
Oberg, J. A., Glade Bender, J. L., Sulis, M. L., Pendrick, D., Sireci, A. N., Hsiao, S. J., Turk, A. T., Dela Cruz, F. S., Hibshoosh, H., Remotti, H., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0389-6 · Cited by 188
“Spl) in a patient with AML referred for transplantation for persistent thrombocytopenia following chemotherapy [41].”
BackgroundSomatic and germline genomics in paediatric acute lymphoblastic leukaemia
Pui, C.-H., Nichols, K. E., & Yang, J. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0136-6 · Cited by 177
RUNX family: Regulation and diversification of roles through interacting proteins
Chuang, L. S. H., Ito, K., & Ito, Y. (2013) · International Journal of Cancer · doi:10.1002/ijc.27964 · Cited by 184
“Moreover, familial platelet disorder (FPD) with propensity to myeloid malignancy (FPD/ AML) is attributed to inherited germline RUNX1 mutations.(14,15) RUNX1 was also reported to serve as tumor suppressor in TLX1- and TLX3-mediated T-ALL.”
BackgroundHow I diagnose and manage individuals at risk for inherited myeloid malignancies
The University of Chicago Hematopoietic Malignancies Cancer Risk Team (2016) · Blood · doi:10.1182/blood-2016-05-670240 · Cited by 182
“CEBPA, ETV6, GATA2, RUNX1, and TP53 are transcription factors that localize to the nucleus.(6,8,9,17-19,34,35,86) TERT and TERC both constitute subunits of telomerase and also localize to the nucleus.”
BackgroundGastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice.
Miyoshi, H., Nakau, M., Ishikawa, T. O., Seldin, M. F., Oshima, M., & Taketo, M. M. (2002) · PubMed · Cited by 186
AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML
Licht, J. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204593 · Cited by 180
“The RHD is a target of mutation in familial platelet disorder (FPD) associated with a predisposition to leukemia (Song et al., 1999) and is mutated in sporadic cases of AML and MDS without chromosomal translocations (Imai et al., 2000; Osato et al., 1999; Preudhomme et al., 2000).”
BackgroundPreudhomme, C., Renneville, A., Bourdon, V., Philippe, N., Roche-Lestienne, C., Boissel, N., Dhedin, N., André, J.-M., Cornillet-Lefebvre, P., Baruchel, A., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168260 · Cited by 173
“Two additional somatic alterations were identified in this patient at AML stage: a K-RAS mutation and a t(1;3)(p36; q26) inducing a PRDM16 overexpression.”
BackgroundMolecular and Transcriptional Regulation of Megakaryocyte Differentiation
Shivdasani, R. A. (2001) · STEM CELLS · doi:10.1634/stemcells.19-5-397 · Cited by 180
RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis
Lam, K. (2012) · Frontiers in Bioscience · doi:10.2741/3977 · Cited by 167
“While haploinsufficiency of RUNX1 may predispose patients to FPD/AML, biallelic mutations in RUNX1 resulting from a second hit may lead to full on leukemia (96).”
BackgroundInfluentialZelent, A., Greaves, M., & Enver, T. (2004) · Oncogene · doi:10.1038/sj.onc.1207672 · Cited by 174
“Heritable mutations in the AML1 RUNT DBD were also found to be associated with familial platelet disorder and predisposition to acute myelogenous leukaemia (Osato et al., 1999; Song et al., 1999).”
Background
Metadata
- Authors
- Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., Loh, M., Felix, C., Roy, D.-C., Busque, L., Kurnit, D., Willman, C., Gewirtz, A. M., Speck, N. A., Bushweller, J. H., Li, F. P., Gardiner, K., Poncz, M., Maris, J. M., & Gilliland, D. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Brown University (US)
- University of Pennsylvania (US)
- Leicester Royal Infirmary (GB)
- St Vincent Hospital (US)
- Hôpital Maisonneuve-Rosemont (CA)
- University of Michigan (US)
- University of New Mexico (US)
- Dartmouth College (US)
- University of Virginia (US)
- Harvard University (US)
- Roosevelt Institute (US)
- Corresponding author
- Gilliland, D. Gary
- ORCID
- Venue
- Nature Genetics
- Published
- 1999-10
- Volume
- 23
- Issue
- 2
- Pages
- 166-175
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1739103212
- Cited by
- 1,100
- References
- 49
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 27 · 2023: 32 · 2022: 29 · 2021: 36 · 2020: 46 · 2019: 33 · 2018: 26 · 2017: 61 · 2016: 54 · 2015: 35 · 2014: 30 · 2013: 33 · 2012: 53
- FWCI
- 25.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (7r29ai039536-04)
- National Cancer Institute (R01CA081932, R01-CA78545, R01 CA81932, R01CA078545)
- National Institute of Allergy and Infectious Diseases (R29 AI39536)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- RUNX1, haploinsufficiency, autosomal dominant inheritance, missense mutations, megakaryopoiesis, megakaryocyte colony formation, platelet disorders, chromosome 21q, nonsense mutation, intragenic deletion
- MeSH terms
- Amino Acid Sequence, Base Sequence, Blood Platelets, Chromosome Mapping, Colony-Forming Units Assay, DNA Mutational Analysis, DNA-Binding Proteins, Family Health, Female, Genotype, Hematopoiesis, Heterozygote, Humans, Male, Megakaryocytes, Molecular Sequence Data, Mutation, Pedigree, Proto-Oncogene Proteins, RNA, Sequence Homology, Nucleic Acid, Thrombocytopenia, Transcription Factors, Leukemia, Myeloid, Acute, Sequence Deletion, Sequence Homology, Amino Acid, In Situ Hybridization, Fluorescence, Microsatellite Repeats, Genetic Predisposition to Disease, Reverse Transcriptase Polymerase Chain Reaction, Core Binding Factor Alpha 2 Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.